Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
UNI-DUR vs DECASPRAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.
Treatment of asthma (chronic stable and acute exacerbations),Chronic obstructive pulmonary disease (COPD) maintenance therapy,Apnea of prematurity (off-label),Ureteral colic (off-label)
Inflammatory dermatoses (e.g., eczema, dermatitis),Allergic skin reactions,Psoriasis,Lichen planus,Discoid lupus erythematosus
200-400 mg orally every 12 hours; maximum 800 mg daily.
2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
The terminal elimination half-life is approximately 3-4 hours in adults. This short half-life is consistent with its classification as a long-acting glucocorticoid due to high potency and prolonged tissue effects, not extended plasma presence.
Theophylline is primarily metabolized in the liver by cytochrome P450 enzymes CYP1A2 (major) and CYP2E1, CYP3A4 (minor). It undergoes N-demethylation and oxidation to form metabolites (1-methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid). Approximately 10% is excreted unchanged in urine.
Dexamethasone is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
Decaspray (dexamethasone) is primarily metabolized in the liver, with less than 10% excreted unchanged in urine. Minor biliary excretion occurs, but fecal elimination is negligible. Overall, renal excretion accounts for >90% as metabolites, with <10% as parent drug.
95% bound to albumin.
Approximately 77% bound to serum proteins, primarily albumin and corticosteroid-binding globulin (CBG).
Vd 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid.
Volume of distribution is approximately 0.8 L/kg (range 0.5-1.0 L/kg). This indicates moderate distribution into tissues, with higher penetration into CNS compared to other glucocorticoids.
Oral: 85-95% (immediate-release); 70-80% (extended-release).
Oral bioavailability is approximately 80-90%. Intramuscular bioavailability is nearly 100% due to complete absorption. Intranasal bioavailability is low (<1%) due to local administration, but systemic absorption can occur with high doses.
GFR 30-50 m L/min: 200 mg every 12 hours; GFR <30 m L/min: 200 mg every 24 hours; hemodialysis: 200 mg after dialysis.
No adjustment required for any degree of renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: 200 mg every 24 hours.
No adjustment required for Child-Pugh Class A or B. For Child-Pugh Class C, caution advised due to lack of data; monitor for systemic effects.
5-10 mg/kg orally every 12 hours; maximum 400 mg daily.
Children 2-11 years: 1-2 sprays (200-400 mcg) intranasally twice daily. Maximum 4 sprays per day.
Initiate at 200 mg every 12 hours; increase cautiously, monitor renal function.
Same as adult dosing. No specific dose reduction required; monitor for adrenal suppression in prolonged use.
WARNING: Life-threatening adverse events, including seizures, cardiac arrhythmias, and respiratory arrest, can occur with theophylline toxicity. Serum theophylline levels must be monitored closely, and dosing adjusted to maintain therapeutic range (5-15 mcg/m L). Concurrent use with other xanthines (e.g., caffeine) is contraindicated.
None
Therapeutic drug monitoring required due to narrow therapeutic index. Caution in patients with hepatic impairment, heart failure, pneumonia, elderly, and fever (prolonged half-life). Drug interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., smoking, rifampin). Seizure risk at high levels. Cardiotoxicity (atrial/ventricular arrhythmias).
Topical corticosteroids may cause systemic absorption, leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Systemic absorption is increased with use on large surface areas, prolonged use, occlusive dressings, or in pediatric patients. Avoid use on face, groin, or axillae unless directed. Use caution in patients with bacterial, fungal, or viral skin infections; may mask or worsen infection. Discontinue if irritation or sensitization occurs.
Hypersensitivity to theophylline or any component. Concurrent use with ephedrine or other xanthines. Active seizure disorder (relative). Uncontrolled cardiac arrhythmias. Severe hepatic impairment.
Hypersensitivity to dexamethasone or any component of the formulation; untreated bacterial, fungal, or viral skin infections; tuberculous skin lesions; syphilitic skin infections; vaccinia or varicella; perioral dermatitis; rosacea; acne vulgaris; broken or abraded skin.
Food does not affect absorption significantly; however, consistent dietary caffeine intake may increase side effects. A high-protein, low-carbohydrate diet can decrease theophylline clearance; avoid drastic dietary changes.
No known food interactions. Avoid excessive intake of potassium-rich foods if prolonged use on large areas to mitigate risk of hypokalemia.
Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood flow, growth restriction, and premature labor inhibition. Avoid use unless benefit outweighs risk.
FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and premature closure of ductus arteriosus with prolonged use.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance to mother.
Limited data; small amounts of dexamethasone excreted into breast milk; M/P ratio approximately 0.3-0.5. Theoretical risk of adrenal suppression; avoid high doses or monitor infant for growth and adrenal function.
No standard dose adjustments. Increased clearance and volume of distribution during pregnancy may require dose titration based on clinical response and serum drug levels if applicable.
No standard dose adjustment; use lowest effective dose. Increased clearance in third trimester may require higher doses to achieve therapeutic effect; monitor clinical response and adjust accordingly.
UNI-DUR (theophylline extended-release) requires monitoring of serum theophylline concentrations to maintain efficacy and avoid toxicity; therapeutic range is 5-15 mcg/m L. Avoid use in patients with active peptic ulcer disease or seizure disorders. Dosage adjustments needed in hepatic impairment, heart failure, and with concurrent use of drugs that affect CYP1A2 and CYP3A4.
Decaspray (dexamethasone topical aerosol) is a potent corticosteroid for dermatologic use. Avoid use on infected skin without concurrent anti-infective therapy. Limit application to small areas and use sparingly to minimize systemic absorption. Do not use on face, groin, or axillae due to risk of atrophy. Discontinue if irritation or sensitization occurs.
Take UNI-DUR exactly as prescribed, at the same time each day, with or without food.,Do not crush or chew the tablets; swallow whole.,Avoid smoking and limit caffeine intake as they can alter theophylline levels.,Report symptoms of toxicity such as nausea, vomiting, insomnia, palpitations, or seizures.,Do not change brands or formulations without consulting your healthcare provider.
Apply a thin film only to affected skin areas as directed.,Do not cover the treated area with bandages unless instructed by your doctor.,Avoid contact with eyes, mouth, or open wounds.,Do not use on diaper rash or under diapers.,Wash hands after application unless treating hands.,Inform your doctor if condition worsens or does not improve after 2 weeks.,Do not use for other conditions without consulting a healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about UNI-DUR vs DECASPRAY, answered by our medical review team.
UNI-DUR is a Methylxanthine Bronchodilator that works by UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.. DECASPRAY is a Intranasal Corticosteroid that works by Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between UNI-DUR and DECASPRAY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of UNI-DUR is: 200-400 mg orally every 12 hours; maximum 800 mg daily.. The standard adult dose of DECASPRAY is: 2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between UNI-DUR and DECASPRAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. UNI-DUR is classified as Category C. Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood. DECASPRAY is classified as Category C. FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and pre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.